This is the drug that we recently gave a million dollar grant to help support and speed up it's development! The mutation (H3K27 M)
is very common in DIPG, and common in midline and thalmic malignant gliomas, more so in younger GBM patients. This experimental drug is in clinical trials. Check your pathology report to see if you have this mutation. If you do, contact us and we can help you find a trial. (It is so common in DIPG that no biopsy is needed to get into the trials for that tumor type - it is assumed they all have this)
I love this type of research. Invadopoia are small projections from the edges of tumnor cells that help allow them to move. Without the ability to move, the tumor is much less dangerous and more sensitive to normal treatments. This is a highly underappreciated target and they found 2 existing drugs which may target this. Of course, it is just theory now and needs to be tested but it is a promising approach!
Dr Schulder will be speaking about the new version of the Gamma Knife, but will also answer questions on any brain tumor related topic!
I am a big fan of Optune. It is the most effective approved treatment for gbms, but it is not good enough by itself. We need to find ways to make it work better. There are about 16 clinical trials going on now that involve Optune and ways to make it work better. Any of these trials are worthwhile to try. Experiments like this are needed to identify candidates for the trials.
This is a new STAT3 inhibitor. STAT3 has been known as a good target for brain tumors but until now we did not have a good drug to target it. This was just the first in human doses of the drug so it is way too early to tell if it will work, but it may become an important tool in the ultimate cocktail.
Researchers at Duke identified why brain tumor patients have such low t cell counts - as low as that of AIDs patients. Now we just need to figure out how to use this information!
I would like to emphasis that this is a collaboration between the Musella Foundation, the Cure Starts Now Foundation, and the Michael Mosier Defeat DIPG Foundation! we couldn't have done this without them.
Interesting results, but in a small number of patients.
These are nice meetings for anyone who has a brain tumor or cares for someone with a brain tumor
A video segment about glioblastoma
Congratulations to my good friend Dellann! She is the perfect person for that job which hopefully will result in better, more "patient friendly" clinical trials!
We have not received any new funding but a few grants expired and we recycle the funds, so we have enough money to only make a few grants.
I usually do not report on financial stuff, but this is good news for the brain tumor community. It shows that a brain tumor treatment can be a financial success and this will encourage other companies to enter this space!
These are always very interesting and worth going for anyone dealing with a brain tumor.
Interesting study - but it is only in the test tube. We follow Aspirin in the virtual trial but nobody has recorded it - I know many people must be taking it long term for heart protection - they just aren't recording it. If you are in the virtual trial and take long term Aspirin , please go back and post an update so we can see if it helps!
This is a new trial for newly diagnosed GBM or recurrent high grade glioma in adults (age 18+).
Good news.. We expected there would be no problems, and this confirms it.
This drug has a strange past - it did very good in early trials for breast cancer but failied in the large phase 3 trial. It seems to have lottle toxcicity and the early brain tumor trial showed good results so it is worth a try again
This may be a way to improve the results of Optune.